Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intravitreal anti-VEGF · 1 trial · 1 indication
Measure the number of intravitreal anti VEGF injections from Month 1 through Month 12 following an intravitreal injection of AAVCAGsCD59 at Day 7
| Arm | Type | Description |
|---|---|---|
| AAVCAGsCD59 Treated Arm | EXPERIMENTAL | An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity. |
| Name | Type | Description |
|---|---|---|
| Intravitreal anti-VEGF | DRUG | Intravitreal injection of anti-VEGF at Day 0 then monthly as needed |
| Intravitreal AAVCAGsCD59 | BIOLOGICAL | An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once |
| Oral prednisolone | DRUG | A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients |
Inclusion Criteria: 1. Men or women 50 years of age or older. 2. Treatment naive Wet AMD with no evidence of subretinal fibrosis under the fovea. 3. Presence of intraretinal and/or subretinal fluid on OCT. 4. Best corrected visual acuity (BCVA) Snellen equivalent 20/25 to 20/400 in the study eye us...
Intravitreal anti-VEGF is an investigational small molecule being developed for the treatment of Wet Age-related Macular Degeneration. It is administered intravitreally and is currently in Phase 1 clinical development. The drug is being studied to evaluate its safety and potential efficacy in patients with this condition.
Intravitreal anti-VEGF is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 1 clinical development for the treatment of Wet Age-related Macular Degeneration.
Intravitreal anti-VEGF is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to evaluate its use in patients with Wet Age-related Macular Degeneration.
Intravitreal anti-VEGF has one completed clinical trial, identified as NCT03585556, titled 'AAVCAGsCD59 for the Treatment of Wet AMD'. This Phase 1 trial enrolled 25 participants in the United States and was an uncontrolled, non-randomized study. The trial included patients aged 50 years and older with Wet Age-related Macular Degeneration.
Intravitreal anti-VEGF is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Wet Age-related Macular Degeneration. The drug has completed a Phase 1 clinical trial, but it remains under investigation and has not received regulatory approval.